Prognostic relevance of TTF-1 and MMP-9 expression in advanced lung adenocarcinoma
Contribuinte(s) |
UNIVERSIDADE DE SÃO PAULO |
---|---|
Data(s) |
19/10/2012
19/10/2012
2009
|
Resumo |
Background: The thyroid transcription factor-1 (TTF-1) is a tissue-specific transcription factor that Could playan important role in cell differentiation and morphogenesis of lung tumors. Matrix metalloproteinase-9 (MMP-9) is a protease commonly expressed in non-small cell lung cancer, conferring angiogenic and metastatic potential. Methods: We assessed TTF-1 and MMP-9 tumor expression by immunohistochemistry in 51 patients with lung adenocarcinoma, stage 11113 or IV, treated with platinum regimens. A bicategorical prognostic model was obtained using the Kaplan-Meier method, COX regression, and conjunctive consolidation. Results: The median expression of TTF-1 was 30.0% (range: 0-85.9%). All tumors expressed MMP-9 (median: 78.7%: range: 15.2-96.1%). Median survival was 41.6 weeks, with estimated 1- and 2-year survival rates of 45.0% and 22.0%, respectively. Poor performance status (Karnofsky scale) - hazards ratio(HR): 1.03. 95% confidence interval (CI): 1.01-1.06: low TTF-1 expression (<40%) - FIR: 4.00, 95% CI: 1.75-9.09: and high MMP-9 expression (>= 80%) - HR: 2.82, 95% CI: 1.30-6.08 were independent prognostic factors. Patients could be stratified in three death risk groups according to markers expression: low risk (high TTF-1 and low MMP-9; median survival: 127.6 weeks), intermediate risk (low TTF-1 OF high MMP-9; median survival: 39.0 weeks): and high risk (low TTF-1 and high MMP-9: median survival: 16.4 weeks). Conclusion: TTF-1 and MMP-9 tumor expression as detected by immunohistochemistry may allow identification of different, clinically meaningful, prognostic groups of advanced lung adenocarcinoma patients treated with platinum regimens. (C) 2008 Elsevier Ireland Ltd. All rights reserved. National Council for Scientific and Technological Development [CNPq] Foundation for the Support of Research of the State of Sao Paulo [FAPESP] Universidade de São Paulo - Laboratory for Medical Research [LIM05] FM/USP |
Identificador |
LUNG CANCER, v.64, n.1, p.105-109, 2009 0169-5002 http://producao.usp.br/handle/BDPI/22638 10.1016/j.lungcan.2008.07.017 |
Idioma(s) |
eng |
Publicador |
ELSEVIER IRELAND LTD |
Relação |
Lung Cancer |
Direitos |
restrictedAccess Copyright ELSEVIER IRELAND LTD |
Palavras-Chave | #Lung adenocarcinoma #NSCLC #Thyroid transcription factor-1 #Matrix metalloproteinase-9 #Immunohistochemistry #Survival analysis #Prognostic factors #THYROID TRANSCRIPTION FACTOR-1 #FACTOR-I EXPRESSION #CELL #CANCER #MATRIX-METALLOPROTEINASE-9 #SURVIVAL #CARCINOMA #PATHWAYS #PREDICTS #Oncology #Respiratory System |
Tipo |
article original article publishedVersion |